SURMODICS AND ABBEYMOOR MEDICAL TO JOINTLY DEVELOP DRUG-DEVICE CONVERGENCE PRODUCTS TO TREAT DISEASES OF THE PROSTATE

SurModics, Inc., and AbbeyMoor Medical announced today the signing of an agreement to jointly develop products intended to site specifically deliver therapeutic agents to treat various diseases of the prostate, such as prostatitis and prostate cancer. AbbeyMoor has developed The Spanner Prostatic Stent, which is designed to manage prostatic obstruction in men. AbbeyMoor recently completed a multi-center clinical trial and is progressing with the Pre-Market Approval process with the U.S. Food and Drug Administration. The PMA was filed with the FDA in March 2006. Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20060628005809&newsLang=en)